Medpace Holdings, Inc. cash flow to debt ratio of 284.73% indicates that the company generates enough cash to cover a substantial portion of its debt. This level indicates very strong financial health.

Medpace Holdings, Inc.'s free cash flow has increased 19.15% from $572.27M last year to $681.87M, signaling increasing performance

Medpace Holdings, Inc.'s debt to equity ratio is 0.28, which means that the company's assets are healthy financed, signaling financial stability.

Medpace Holdings, Inc.'s debt has increased relative to shareholder equity from 0.18 last year to 0.28 today, signaling weakened financials

Medpace Holdings, Inc. has a net cash position, so leverage is healthy.

Interest expense is not separately reported in Medpace Holdings, Inc.'s latest filing, so interest coverage cannot be calculated.

Medpace Holdings, Inc.'s profit margin has decreased (7.87%) in the last year from 19.17% to 17.67%, signaling decreasing performance

Medpace Holdings, Inc.'s short-term liabilities of $1.34B exceed its short-term assets of $989.62M, signaling financial risk

Medpace Holdings, Inc.'s return on assets of 23.89% is higher than the 5.00% threshold, indicating efficient asset utilization

Medpace Holdings, Inc.'s return on equity of 110.15%, is higher than 15.00%, indicating good performance

Medpace Holdings, Inc.'s operating cash flow exceeds its net income, indicating high-quality earnings backed by actual cash generation

Medpace Holdings, Inc. had positive net income in 5 out of 5 years, indicating stable and consistent earnings

Medpace Holdings, Inc. has positive free cash flow, indicating the company generates cash after capital expenditures

Medpace Holdings, Inc. has a free cash flow yield of 4.06%, which is above the 2.00% threshold, indicating strong cash generation relative to market value

Medpace Holdings, Inc.'s yearly earnings has increased 11.56% since last year from $404.39M to $451.12M, signaling increasing performance

Medpace Holdings, Inc.'s yearly revenue has increased 19.97% since last year from $2.11B to $2.53B, signaling increasing performance

ROIC 77.00% (Source: FMP key-metrics). At or above the 10% threshold. Score: 2 of 2. The company is generating returns above the upper end of the typical US weighted-average cost of capital range under this definition of invested capital.

Medpace Holdings, Inc.'s 3-year revenue CAGR of 20.12% is positive, indicating growing revenue over the past 3 years

Medpace Holdings, Inc. had revenue growth in 5 out of 5 years, indicating consistent revenue performance

Medpace Holdings, Inc. had positive ROE in 5 out of 5 years, indicating consistent and reliable returns on equity

Medpace Holdings, Inc. is overvalued relative to its fair value price of 432.45 based on Discounted Cash Flow model

Medpace Holdings, Inc. has an earnings yield of 2.88%, which is below the 4.00% threshold, indicating the stock may be expensive relative to its earnings

Medpace Holdings, Inc. is overvalued relative to its fair value price of 148.48 based on EBITDA multiple model

Medpace Holdings, Inc. has an EV/EBITDA ratio of 29.04x, which exceeds the 20.00x threshold, indicating the stock may be overvalued relative to its operating earnings

Medpace Holdings, Inc. is overvalued relative to its fair value price of 337.85 based on Earnings Fair Value model

Medpace Holdings, Inc. has a PEG-ratio over 1 which is considered overvalued

Medpace Holdings, Inc. has a price-to-book ratio of 39.31x, which exceeds the 5.00x threshold, indicating the stock may be overvalued relative to its book value

Medpace Holdings, Inc. has a price-to-sales ratio of 6.13x, which is below the 8.00x threshold, indicating reasonable valuation relative to its revenue